Ductal carcinoma in situ: Risk factors and impact of screening

Journal of the National Cancer Institute - Monographs

Volumn , Issue 41, 2010, Pages 113-116

  Virnig, Beth A ^a,b   Wang, Shi Yi ^a   Shamilyan, Tatyana ^a   Kane, Robert L ^a   Tuttle, Todd M ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST NECROSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER SCREENING; CHEMOPROPHYLAXIS; COCHRANE LIBRARY; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTITIS; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; TUMOR NECROSIS; ADULT; AGE DISTRIBUTION; AGED; BREAST TUMOR; INCIDENCE; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PAGET NIPPLE DISEASE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICS; UTILIZATION REVIEW;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOPREVENTION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TAMOXIFEN; YOUNG ADULT;

EID: 79952200165     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgq024     Document Type: Article

References (35)

1. Ries LaG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005.Bethesda, MD: National Cancer Institute; 2008. http://seer.cancer.gov/csr/1975_2005/. Accessed March 28, 2010.
2. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005;14(4):1008-1011.
3. Innos K, Horn-Ross PL. Recent trends and racial/ethnic differences in the incidence and treatment of ductal carcinoma in situ of the breast in California women. Cancer. 2003;97(4):1099-1106.
4. Wohlfahrt J, Rank F, Kroman N, et al. A comparison of reproductive risk factors for CIS lesions and invasive breast cancer. Int J Cancer. 2004;108(5):750-753.
5. Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):76-82.
6. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2000;9(7):697-703.
7. Vamre TB, Stalsberg H, Thomas DB. Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use. Int J Cancer. 2006;118(11):2827-2831.
8. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001;93(23):1811-1817.
9. Bohlke K, Cramer DW, Trichopoulos D, et al. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology. 1998;9(5):570-573.
10. Claus EB, Stowe M, Carter D. Oral contraceptives and the risk of ductal breast carcinoma in situ. Breast Cancer Res Treat. 2003;81(2):129-136.
11. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006;7(11):910-918.
12. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA. 1999;281(22):2091-2097.
13. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21(23):4314-4321.
14. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253.
15. Gill JK, Maskarinec G, Pagano I, et al. The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res. 2006;8(3):R30.
16. Kerlikowske K, Walker R, Miglioretti DL, et al. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008;100(23):1724-1733.
17. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2000;9(7):697-703.
18. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19(4):924-930.
19. Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer. 2004;100(10):2079-2083.
20. Miller AB, To T, Baines CJ, et al. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst. 2000;92(18):1490-1499.
21. Miller AB, To T, Baines CJ, et al. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137(5, pt 1):305-312.
22. Bjurstam N, Bjorneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. Cancer. 2003;97(10):2387-2396.
23. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr. 1997;22:27-30.
24. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
25. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38(4):625-651.
26. Roberts MM, Alexander FE, Anderson TJ, et al. The Edinburgh randomised trial of screening for breast cancer: description of method. Br J Cancer. 1984;50(1):1-6.
27. Frisell J, Lidbrink E, Hellstrom L, et al. Followup after 11 years-update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Res Treat. 1997;45(3):263-270.
28. Duffy SW, Agbaje O, Tabar L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005;7(6):258-265.
29. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546-1554.
30. Smith-Bindman R, Chu PW, Miglioretti DL, et al. Comparison of screening mammography in the United States and the United Kingdom. JAMA. 2003;290(16):2129-2137.
31. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
32. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817-824.
33. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282.
34. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
35. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751-1761.